Table 3.
Adjusted odds ratios for biologic monotherapy vs combination in biologic-naive patients
| Adjusted OR (95 % CI) | Model 1a (n = 3,861)b | Model 2a (n = 2,823)b | Model 3a (n = 644)b |
|---|---|---|---|
| History of hepatic disease | 6.50 (3.20–13.07) | 7.49 (3.19–17.58) | 5.20 (0.95–28.49) |
| History of malignancy | 3.79 (1.64–8.73) | 2.78 (1.02–7.59) | 1.00 (0.19–5.40) |
| Swollen joint count | 0.97 (0.95–0.99) | 0.96 (0.95–0.98) | 0.98 (0.94–1.02) |
| Use of biologic approved for MT | 1.47 (1.20–1.81) | 1.45 (1.13–1.86) | 1.93 (1.08–3.43) |
| Initiated after 2006 | 0.83 (0.68–1.00) | 0.79 (0.63–0.99) | – |
| Erosions | – | 0.84 (0.68–1.03) | 0.96 (0.62–1.49) |
| History of neutropenia | – | – | 4.89 (1.16–20.59) |
| Random effect of individual physician’s treatment decisions | 1.89 (1.66–2.23) | 1.86 (1.61–2.25) | 1.58 (1.23–2.72) |
OR > 1 implies that monotherapy is more likely
CI confidence interval, MT monotherapy, OR odds ratio
aThree different models with various combinations of fixed effects from independent variables described above and a random effect of individual physician’s treatment decisions were fitted
bModels were fitted using available data among 3,923 previously biologic-naive patients initiating a biologic therapy